CHDI
Evotec and CHDI Foundation extend strategic drug discovery collaboration in Huntington’s disease
Hamburg, Germany, 28 May 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) has announced the extension of its 20-year collaboration with CHDI Foundation, Inc. (“CHDI”) ...Read More
Huntington Study Group and CHDI Foundation collaborate on Enroll-HD
Rochester and New York City, New York, July 25, 2023 – HSG Clinical Research, Inc.—the Huntington Study Group’s clinical research organization (CRO) and wholly owned subsidiary (collectively referred to here as HSG)—has begun ...Read More
Huntington’s Disease Image Harmonization Consortium secures new member and funding to complete large-scale analysis of brain changes using IXIQ.Ai
New York, NY / London, UK, July, 12th 2023; The Huntington’s Disease Imaging Harmonization (HD-IH) Consortium, founded last year to conduct an unprecedented harmonization analysis of more than 6,000 participant-visit magnetic resonance images (MRIs ...Read More
European Medicines Agency issues qualification opinion that Enroll-HD can provide data and infrastructure support for post-authorization monitoring of medical products for Huntington’s disease
New York, NY, September 21, 2022; The European Medicines Agency (EMA) has issued a qualification opinion that details facets of the Enroll-HD registry, core observational study, and clinical research platform that are especially suited to post-author ...Read More
Postcard from Palm Springs 2022
The Postcards are a series of short videos aimed at non-scientists that convey the major themes, scientific breakthroughs, and clinical trial updates from each year’s Huntington’s Disease Therapeutics Conference held (most usually) in Palm Spring ...Read More